Kyle Carver Acquires 1,000 Shares of Evommune (NYSE:EVMN) Stock

Evommune, Inc. (NYSE:EVMN) CFO Kyle Carver bought 1,000 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were purchased at an average price of $13.26 per share, with a total value of $13,260.00. Following the completion of the acquisition, the chief financial officer directly owned 60,335 shares in the company, valued at $800,042.10. This trade represents a 1.69% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kyle Carver also recently made the following trade(s):

• On Thursday, May 28th, Kyle Carver sold 18,175 shares of Evommune stock. The shares were sold at an average price of $22.84, for a total transaction of $415,117.00.

Evommune Stock Down 2.1%

Evommune stock traded down $0.28 during mid-day trading on Friday, reaching $13.23. 585,866 shares of the company’s stock were exchanged, compared to its average volume of 1,374,484. Evommune, Inc. has a twelve month low of $12.07 and a twelve month high of $33.20. The company has a market cap of $476.40 million and a P/E ratio of -1.39. The company has a fifty day moving average of $20.37 and a 200-day moving average of $22.01.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. Equities research analysts expect that Evommune, Inc. will post -2.83 earnings per share for the current fiscal year.

Institutional Trading of Evommune

Large investors have recently modified their holdings of the business. Strs Ohio acquired a new position in Evommune in the 1st quarter valued at about $41,000. China Universal Asset Management Co. Ltd. acquired a new position in Evommune in the fourth quarter valued at $34,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Evommune during the 4th quarter worth about $179,000. XTX Topco Ltd purchased a new position in shares of Evommune in the 4th quarter valued at $321,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Evommune during the fourth quarter worth about $335,000.

Analyst Ratings Changes

EVMN has been the topic of a number of recent analyst reports. William Blair downgraded Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. HC Wainwright downgraded shares of Evommune from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 30th. Morgan Stanley dropped their price target on Evommune from $55.00 to $26.00 and set an “overweight” rating on the stock in a research note on Tuesday, June 30th. Oppenheimer started coverage on shares of Evommune in a report on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Clear Str raised shares of Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.62.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.